Loading...
Market
What will be the cost reduction percentage in IVF using GametoGen's iPSC technology by end of 2025?
2
Resolution / Starting Odds
Less than 20% • 25%
20% to 39% • 25%
40% to 59% • 25%
60% or more • 25%
Industry reports or studies published in reputable journals
Story
GametoGen Achieves First Live Birth Using iPSC Technology in IVF, Reducing Hormone Injections by 80% and Treatment to Three Days
Dec 16, 2024, 04:09 PM
GametoGen, a next-generation IVF startup, has announced the first successful live birth using its innovative technology, which utilizes induced pluripotent stem cell (iPSC)-derived ovarian cells. This groundbreaking achievement marks a significant milestone in reproductive technology, as the company claims it is the first human birth resulting from iPSC technology. The new method reportedly replaces 80% of the hormone injections typically required in traditional IVF and shortens treatment cycles to just three days. The announcement has garnered attention for its potential to revolutionize access to IVF and improve outcomes for families seeking fertility assistance.
View original story
Similar markets
More than 50% • 25%
25% to 50% • 25%
10% to 25% • 25%
Less than 10% • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Yes, all major clinics • 25%
Yes, more than half • 25%
Yes, less than half • 25%
No • 25%
Significant Breakthrough • 25%
Moderate Improvement • 25%
No Significant Change • 25%
Setbacks in Technology • 25%
Yes • 50%
No • 50%
6% to 10% • 25%
0% to 5% • 25%
11% to 15% • 25%
More than 15% • 25%
Yes • 50%
No • 50%
0-5% • 25%
6-10% • 25%
11-15% • 25%
16% or more • 25%
80% or less • 25%
81% to 89% • 25%
90% to 95% • 25%
More than 95% • 25%